Recbio First Biotech To Brave A Hong Kong IPO In 2022

mRNA Contender For Omicron?

 
• By Dexter Jie Yan
  
Stock Exchange STAR Market
Recbio’s IPO filing notable given share falls for Hong Kong-listed biotechs • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Focus On Asia